Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer, Rare Disease Drugs Among New China Approvals

Takeda, Bayer Gain Along with Dompe, Henlius

Executive Summary

Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.

You may also be interested in...



Chinese Firms At JPM Not About China, It’s Time To Go Global

From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.

Vaccine, Antibody Race On As Omicron Spreads In China

An oral vaccine candidate from Hong Kong and domestically-developed antivirals and antibodies join the ongoing development fight as Tianjin city reports new Omicron outbreak.

Xian Under Lockdown, mRNA Vaccines Remain Elusive In China

A relatively large outbreak in another major Chinese city after original epicenter Wuhan heightens the urgency for a more effective mRNA vaccine.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel